FBIO|Fortress Biotech Inc|Price:2.410|Chg%:0.11

More Details of Fortress Biotech Inc Company

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.

Fortress Biotech Inc Info



Ticker SymbolFBIO

Company nameFortress Biotech Inc

IPO dateNov 17, 2011

CEORosenwald (Lindsay A)

Number of employees101

Security typeOrdinary Share

Fiscal year-endNov 17

Address1111 Kane Concourse

CityBAY HARBOR ISLANDS

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code33154

Phone17816524500

Websitehttps://www.fortressbiotech.com/

Ticker SymbolFBIO

IPO dateNov 17, 2011

CEORosenwald (Lindsay A)

Company Executives of Fortress Biotech Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Lindsay A. Rosenwald, M.D.

Executive Chairman of the Board, President, Chief Executive Officer

4.59M

--

Mr. Michael S. Weiss, J.D.

Executive Vice Chairman - Strategic Development, Director

2.28M

--

Mr. Dov Klein, CPA

Independent Director

130.10K

+57.91%

Mr. David Jin

Chief Financial Officer and Head of Corporate Development

21.57K

+36.93%

Dr. Lucy Lu, M.D.

Chief Strategy Officer

5.22K

--

Dr. Jimmie Harvey, Jr., M.D.

Independent Director

--

Mr. J. Jay Lobell, J.D.

Independent Director

--

Mr. Malcolm I. Hoenlein, Ph.D.

Independent Director

--

Mr. Kevin L. Lorenz, J.D.

Independent Director

--

Ms. Jaclyn Jaffe

Investor Relations

--

Name

Name/Position

Position

Shareholding

Change

Dr. Lindsay A. Rosenwald, M.D.

Executive Chairman of the Board, President, Chief Executive Officer

4.59M

--

Mr. Michael S. Weiss, J.D.

Executive Vice Chairman - Strategic Development, Director

2.28M

--

Mr. Dov Klein, CPA

Independent Director

130.10K

+57.91%

Mr. David Jin

Chief Financial Officer and Head of Corporate Development

21.57K

+36.93%

Dr. Lucy Lu, M.D.

Chief Strategy Officer

5.22K

--

Dr. Jimmie Harvey, Jr., M.D.

Independent Director

--

Revenue Breakdown

Currency: USDUpdated: Apr 2, 2025

FY2023

FY2023Q4

FY2022

FY2022Q4

FY2021

FY2019

By BusinessUSD

Name

Revenue

Proportion

Targadox®

3.20M

3.79%

Exelderm®

2.40M

2.83%

Ximino®

287.00K

0.34%

Relevant data have not been disclosed by the company yet.

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Targadox®

3.20M

3.79%

Exelderm®

2.40M

2.83%

Ximino®

287.00K

0.34%

Shareholding Stats

Updated: Mon, May 11

Shareholders

Shareholder Types

Shareholders

Proportion

Rosenwald (Lindsay A)

13.81%

Weiss (Michael S)

6.85%

Opaleye Management Inc.

3.28%

Vanguard Capital Management, LLC

2.91%

Summit Financial, LLC

1.32%

Other

71.83%

Shareholders

Proportion

Rosenwald (Lindsay A)

13.81%

Weiss (Michael S)

6.85%

Opaleye Management Inc.

3.28%

Vanguard Capital Management, LLC

2.91%

Summit Financial, LLC

1.32%

Other

71.83%

Shareholder Types

Shareholders

Proportion

Individual Investor

22.79%

Investment Advisor

9.55%

Hedge Fund

5.62%

Investment Advisor/Hedge Fund

2.48%

Research Firm

0.49%

Venture Capital

0.04%

Other

59.02%

Institutional Shareholding



Updated: Wed, Apr 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q1

113

6.02M

18.14%

-871.67K

2025Q4

92

4.96M

26.50%

--

2025Q3

107

4.96M

27.33%

--

2025Q2

114

4.96M

27.45%

+47.82K

2025Q1

116

4.91M

27.75%

-3.29M

2024Q4

121

4.82M

26.63%

+370.47K

2024Q3

123

4.48M

24.67%

+822.95K

2024Q2

130

3.66M

27.39%

+620.10K

2024Q1

155

3.04M

28.91%

-2.56M

2023Q4

162

4.72M

15.96%

+3.18M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Rosenwald (Lindsay A)

4.59M

14.78%

+475.42K

+11.56%

Mar 18, 2026

Weiss (Michael S)

2.28M

7.33%

+475.42K

+26.40%

Mar 18, 2026

Opaleye Management Inc.

1.09M

3.51%

+1.09M

--

Dec 31, 2025

Summit Financial, LLC

439.93K

1.42%

-4.82K

-1.08%

Dec 31, 2025

Shikiar Asset Management, Inc.

278.47K

0.9%

--

Dec 31, 2025

Geode Capital Management, L.L.C.

262.49K

0.85%

+18.07K

+7.39%

Dec 31, 2025

Northern Trust Investments, Inc.

239.53K

0.77%

+18.90K

+8.56%

Dec 31, 2025

Susquehanna International Group, LLP

229.78K

0.74%

-126.40K

-35.49%

Dec 31, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

iShares Micro-Cap ETF

0.01%

Fidelity Enhanced Small Cap ETF

0%

iShares Micro-Cap ETF

Proportion0.01%

Fidelity Enhanced Small Cap ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

Date

Ex-dividend Date

Type

Ratio

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1

Oct 09, 2023

Merger

15→1